Pub Date : 2025-01-01Epub Date: 2025-10-11DOI: 10.1016/j.lrr.2025.100550
Jiajia Sun, Zhiping Guo
Several genetic risk classification systems based on response to older acute myeloid leukemia patients treated with less-intensive regimens, especially venetoclax (VEN) + hypomethylating agent (HMA), are proposed recently. VEN+HMA improved the outcome of cytogenetic adverse-risk AML, AML with some of MR mutations and/or clonal hematopoiesis (CH) related mutations. DNMT3Amut, IDH1/2mut and NPM1mut were defined as “VEN sensitive mutations”. DDX41mut is identified as a particularly favorable-risk group. Even multi-hit TP53 status did not negatively affect overall survival (OS) of DDX41-mutants. Signaling gene mutations (FLT3-ITDpos and K/NRASmut) are classified as intermediate risk, consistent with their biological associations as mediators of VEN resistance.
{"title":"Unveiling prognosis in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax through novel risk stratification","authors":"Jiajia Sun, Zhiping Guo","doi":"10.1016/j.lrr.2025.100550","DOIUrl":"10.1016/j.lrr.2025.100550","url":null,"abstract":"<div><div>Several genetic risk classification systems based on response to older acute myeloid leukemia patients treated with less-intensive regimens, especially venetoclax (VEN) + hypomethylating agent (HMA), are proposed recently. VEN+HMA improved the outcome of cytogenetic adverse-risk AML, AML with some of MR mutations and/or clonal hematopoiesis (CH) related mutations. <em>DNMT3A</em><sup>mut</sup>, <em>IDH1/2</em><sup>mut</sup> and <em>NPM1</em><sup>mut</sup> were defined as “VEN sensitive mutations”. <em>DDX41</em><sup>mut</sup> is identified as a particularly favorable-risk group. Even multi-hit <em>TP53</em> status did not negatively affect overall survival (OS) of <em>DDX41</em>-mutants. Signaling gene mutations (<em>FLT3-</em>ITD<sup>pos</sup> and <em>K/NRAS</em><sup>mut</sup>) are classified as intermediate risk, consistent with their biological associations as mediators of VEN resistance.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100550"},"PeriodicalIF":0.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145320236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2025-08-08DOI: 10.1016/j.lrr.2025.100538
Mustapha Mechtoune , Fatima Zahra Lahlimi , Illias Tazi , Hanane Rais , Houda Jouihri , Mohammed el Fadli
The association of cutaneous B-cell lymphoma and dermatofibrosarcoma is exceptional. We report the case of a 44-year-old patient with a history of Darier-Ferrand dermatofibrosarcoma who presented with cutaneous B-cell lymphoma characterized by large atypical skin lesions with an aggressive course. The patient was treated with a combination of RCHOP-type chemotherapy and surgical treatment. We shed light on this very rare association whose prognosis depends on early diagnosis and adequate management.
{"title":"Le lymphome cutanée primitif diffus à grandes cellules B : à propos d’un cas Primary cutaneous diffuse large B-cell lymphoma: a case report","authors":"Mustapha Mechtoune , Fatima Zahra Lahlimi , Illias Tazi , Hanane Rais , Houda Jouihri , Mohammed el Fadli","doi":"10.1016/j.lrr.2025.100538","DOIUrl":"10.1016/j.lrr.2025.100538","url":null,"abstract":"<div><div>The association of cutaneous B-cell lymphoma and dermatofibrosarcoma is exceptional. We report the case of a 44-year-old patient with a history of Darier-Ferrand dermatofibrosarcoma who presented with cutaneous B-cell lymphoma characterized by large atypical skin lesions with an aggressive course. The patient was treated with a combination of RCHOP-type chemotherapy and surgical treatment. We shed light on this very rare association whose prognosis depends on early diagnosis and adequate management.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100538"},"PeriodicalIF":0.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145157328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2025-08-21DOI: 10.1016/j.lrr.2025.100536
Huan Liu , Yunxia Sun , Liangliang Li , Yurong Zhang , Yaxiong Zhou , Pengyun Zeng , Lingling Yue
The use of TKIs has significantly improved the prognosis of CML. However, a small subset of patients still experience poor outcomes. We present a rare case of Ph-AML following a diagnosis of CML. The patient achieved CCyR and MMR after 4 months of nilotinib therapy, with sustained deep remission for 3 years. Unexpectedly, the disease developed rapidly to AML. Further investigations revealed the emergence of CCA/Ph- and gene mutations. We retrospectively analyzed previous CML patients with BCR::ABL1 and Ph-negative status in blast crisis from our database and conducted a comprehensive review of the relevant literature.
{"title":"Rapid development of Philadelphia chromosome-negative AML in a CML patient with sustained major molecular response to tyrosine kinase inhibitor therapy","authors":"Huan Liu , Yunxia Sun , Liangliang Li , Yurong Zhang , Yaxiong Zhou , Pengyun Zeng , Lingling Yue","doi":"10.1016/j.lrr.2025.100536","DOIUrl":"10.1016/j.lrr.2025.100536","url":null,"abstract":"<div><div>The use of TKIs has significantly improved the prognosis of CML. However, a small subset of patients still experience poor outcomes. We present a rare case of Ph-AML following a diagnosis of CML. The patient achieved CCyR and MMR after 4 months of nilotinib therapy, with sustained deep remission for 3 years. Unexpectedly, the disease developed rapidly to AML. Further investigations revealed the emergence of CCA/Ph- and gene mutations. We retrospectively analyzed previous CML patients with <em>BCR::ABL1</em> and Ph-negative status in blast crisis from our database and conducted a comprehensive review of the relevant literature.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100536"},"PeriodicalIF":0.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144903128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2025-06-28DOI: 10.1016/j.lrr.2025.100525
M. Dargenio , C. Buquicchio , D. Pastore , L. Aprile , L. Ciuffreda , G. Greco , M. Delia , V. Federico , MP. Fina , D. Seripa , R. Matera , G. Tarantini , A. Maggi , L. Melillo , V. Pavone , P. Musto , G. Specchia , N. Di Renzo
Gemtuzumab Ozogamicin, a monoclonal antibody targeting CD33, linked to calicheamicin, is approved in combination with “3 + 7″ for the treatment of patients with de novo CD33 positive AML. The aim of study was to evaluate the outcome of patients receiving 3 + 7 plus GO as front-line therapy outside clinical trials. Between March 2020 and February 2023, 34 consecutive fit CD33+ AML patients, median age 54.5 years (range, 25–75) were treated. This study confirms the efficacy and toxicity data reported in clinical trials, highlighting the feasibility of GO based chemotherapy also in patients older than 60 years and as a bridge to allo-HSCT.
{"title":"Real-World Efficacy and Safety of Gemtuzumab Ozogamycin (GO) and 3 + 7 regimen in fit newly diagnosed Acute Myeloid Leukemia (AML) patients. A Retrospective multicenter study of “Rete Ematologica Pugliese” (REP)","authors":"M. Dargenio , C. Buquicchio , D. Pastore , L. Aprile , L. Ciuffreda , G. Greco , M. Delia , V. Federico , MP. Fina , D. Seripa , R. Matera , G. Tarantini , A. Maggi , L. Melillo , V. Pavone , P. Musto , G. Specchia , N. Di Renzo","doi":"10.1016/j.lrr.2025.100525","DOIUrl":"10.1016/j.lrr.2025.100525","url":null,"abstract":"<div><div>Gemtuzumab Ozogamicin, a monoclonal antibody targeting CD33, linked to calicheamicin, is approved in combination with “3 + 7″ for the treatment of patients with de novo CD33 positive AML. The aim of study was to evaluate the outcome of patients receiving 3 + 7 plus GO as front-line therapy outside clinical trials. Between March 2020 and February 2023, 34 consecutive fit CD33+ AML patients, median age 54.5 years (range, 25–75) were treated. This study confirms the efficacy and toxicity data reported in clinical trials, highlighting the feasibility of GO based chemotherapy also in patients older than 60 years and as a bridge to allo-HSCT.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100525"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144523811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2025-08-11DOI: 10.1016/j.lrr.2025.100537
Sona Rezaei , Mohammad Mohammadzadeh-Vardin , Keyvan Amirshahrokhi , Mojtaba Amani
Acute myeloid leukemia (AML) often relapses post-chemotherapy due to leukemia stem cells (LSCs), which rely on mitochondria for energy, ROS regulation, and apoptosis. Targeting mitochondrial pathways may overcome LSC resistance. This study evaluated Cytarabine (Ara-C), 2-Deoxy-d-Glucose (2-DG), and their combination on AML-derived KG1-a cells using MTT assays, showing reduced viability with combined treatment. The Magnetic sorting isolated CD34+ (stem-like) and CD34- cells. Flow cytometry revealed increased ROS and decreased mitochondrial membrane potential (MMP) in KG1-a and CD34+ cells with 2-DG and Ara-C, suggesting a promising strategy to target resistant LSCs in AML therapy.
{"title":"The synergistic effect of 2-deoxy-D-glucose and cytarabine on mitochondria of stem-like cells derived from KG1-a","authors":"Sona Rezaei , Mohammad Mohammadzadeh-Vardin , Keyvan Amirshahrokhi , Mojtaba Amani","doi":"10.1016/j.lrr.2025.100537","DOIUrl":"10.1016/j.lrr.2025.100537","url":null,"abstract":"<div><div>Acute myeloid leukemia (AML) often relapses post-chemotherapy due to leukemia stem cells (LSCs), which rely on mitochondria for energy, ROS regulation, and apoptosis. Targeting mitochondrial pathways may overcome LSC resistance. This study evaluated Cytarabine (Ara-C), 2-Deoxy-d-Glucose (2-DG), and their combination on AML-derived KG1-a cells using MTT assays, showing reduced viability with combined treatment. The Magnetic sorting isolated CD34+ (stem-like) and CD34- cells. Flow cytometry revealed increased ROS and decreased mitochondrial membrane potential (MMP) in KG1-a and CD34+ cells with 2-DG and Ara-C, suggesting a promising strategy to target resistant LSCs in AML therapy.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100537"},"PeriodicalIF":0.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144863976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Luspatercept is a novel erythroid maturation agent approved for treating transfusion-dependent anemia in myelodysplastic syndrome (MDS). However, predictive biomarkers and real-world data in Asian populations remain limited.
Methods
We conducted a retrospective cohort study of 66 MDS patients from two Chinese centers, including 22 patients treated with luspatercept and 44 matched controls. Propensity score matching (1:2) was used to adjust for age, sex, risk category, baseline hemoglobin, transfusion burden, and erythropoietin (EPO) levels. Primary endpoints were red blood cell transfusion independence (RBC-TI) ≥8 weeks and hematologic improvement–erythroid (HI-E).
Results
By week 12, 54.5 % of luspatercept-treated patients achieved RBC-TI, compared to 29.5 % in the control group (P < 0.05). Patients with baseline EPO <500 IU/mL had higher RBC-TI rates than those with EPO ≥500 IU/mL (63.6 % vs. 45.5 %). Multivariate analysis identified baseline EPO <500 IU/mL as an independent predictor of response (OR=2.36, 95 % CI: 1.24–4.52, P = 0.008). Safety was acceptable, with no treatment discontinuation due to adverse events.
Conclusion
This first matched real-world study of luspatercept in Chinese MDS patients confirms its efficacy in reducing transfusion needs and identifies baseline erythropoietin level as a clinically meaningful predictor of response. These findings support the integration of EPO-guided selection in personalized treatment strategies.
{"title":"Baseline erythropoietin level predicts Luspatercept response in Chinese patients with myelodysplastic syndrome: a propensity score-matched analysis","authors":"Doudou Chang , Junyan Zhang , Meiling Zhao , Xialin Zhang , Jia Wei , Ruijuan Zhang","doi":"10.1016/j.lrr.2025.100532","DOIUrl":"10.1016/j.lrr.2025.100532","url":null,"abstract":"<div><h3>Background</h3><div>Luspatercept is a novel erythroid maturation agent approved for treating transfusion-dependent anemia in myelodysplastic syndrome (MDS). However, predictive biomarkers and real-world data in Asian populations remain limited.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study of 66 MDS patients from two Chinese centers, including 22 patients treated with luspatercept and 44 matched controls. Propensity score matching (1:2) was used to adjust for age, sex, risk category, baseline hemoglobin, transfusion burden, and erythropoietin (EPO) levels. Primary endpoints were red blood cell transfusion independence (RBC-TI) ≥8 weeks and hematologic improvement–erythroid (HI-E).</div></div><div><h3>Results</h3><div>By week 12, 54.5 % of luspatercept-treated patients achieved RBC-TI, compared to 29.5 % in the control group (<em>P</em> < 0.05). Patients with baseline EPO <500 IU/mL had higher RBC-TI rates than those with EPO ≥500 IU/mL (63.6 % vs. 45.5 %). Multivariate analysis identified baseline EPO <500 IU/mL as an independent predictor of response (OR=2.36, 95 % CI: 1.24–4.52, <em>P</em> = 0.008). Safety was acceptable, with no treatment discontinuation due to adverse events.</div></div><div><h3>Conclusion</h3><div>This first matched real-world study of luspatercept in Chinese MDS patients confirms its efficacy in reducing transfusion needs and identifies baseline erythropoietin level as a clinically meaningful predictor of response. These findings support the integration of EPO-guided selection in personalized treatment strategies.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100532"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144712931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2025-03-18DOI: 10.1016/j.lrr.2025.100507
Mohamed I Sharif, Ahmad S. Alotaibi, Ruah Alyamany, Ali Alahmari, Hanan Alkhaldi, Ayman Saad, Mansour Alfayez
Acute myeloid leukemia (AML) is a heterogeneous disease with diverse molecular cytogenetic characteristics. Philadelphia-positive acute myeloid leukemia, a rare subtype of AML, is traditionally considered a high-risk, with the standard recommendation being an allogeneic hematopoietic cell transplant (HCT) in first remission. More recently, with better characterization and understanding of AML biology, novel therapies have been introduced. Drawing parallels from the advances seen in Philadelphia-positive acute lymphoblastic leukemia (ALL), the question arises whether potent tyrosine kinase inhibitors (TKI), such as ponatinib, in combination with AML-directed therapies, could be used in Philadelphia-positive AML, potentially eliminating the need for HCT in the first remission.
In this report, we review the literature on Philadelphia-positive AML, study a case where HCT was omitted, and explore potential signals that could support successful HCT omission.
{"title":"The road not taken: Exploring non-transplant options in De Novo philadelphia positive acute myeloid leukemia","authors":"Mohamed I Sharif, Ahmad S. Alotaibi, Ruah Alyamany, Ali Alahmari, Hanan Alkhaldi, Ayman Saad, Mansour Alfayez","doi":"10.1016/j.lrr.2025.100507","DOIUrl":"10.1016/j.lrr.2025.100507","url":null,"abstract":"<div><div>Acute myeloid leukemia (AML) is a heterogeneous disease with diverse molecular cytogenetic characteristics. Philadelphia-positive acute myeloid leukemia, a rare subtype of AML, is traditionally considered a high-risk, with the standard recommendation being an allogeneic hematopoietic cell transplant (HCT) in first remission. More recently, with better characterization and understanding of AML biology, novel therapies have been introduced. Drawing parallels from the advances seen in Philadelphia-positive acute lymphoblastic leukemia (ALL), the question arises whether potent tyrosine kinase inhibitors (TKI), such as ponatinib, in combination with AML-directed therapies, could be used in Philadelphia-positive AML, potentially eliminating the need for HCT in the first remission.</div><div>In this report, we review the literature on Philadelphia-positive AML, study a case where HCT was omitted, and explore potential signals that could support successful HCT omission.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100507"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143685841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Acquired factor VII deficiency remains a rare pathology. Only 5 prior reported cases of aFVIID associated with acute myeloid leukemia (AML) have been described in the literature. Despite the rarity of these occurrences, these cases hold significant clinical and scientific implications given the need to understand the physopathology and to establish a therapeutic protocol ensuring better management.
Case presentation
A 38-year-old Arab male with AML was diagnosed at our Department of Clinical Hematology. The initial coagulation panel at admission revealed slightly low prothrombin ratio (PT) of 56 %, while the international normalized ratio (INR) and partial thromboplastin time (PTT) were within normal. Prothrombin complex coagulation factor dosing (PCCFD) confirmed an isolated reduction in the FVII in repeated samples, indicating an isolated deficiency. This patient did not present severe bleeding syndrome and had received conventional chemotherapy (cytarabine (Cytarabine)+ idarubicin). The evolution was marked by cytological remission (CR) with correction of coagulation disorders.
Conclusion
In conclusion, the intricate relationship between isolated aFVIID and AML remains mysterious. Researchers are essential to unravel the intricacies of this rare hematological condition. Further exploration into the molecular mechanisms, prognostic implications, and evolving treatment modalities is crucial to enhance the precision and efficacy of therapeutic interventions.
{"title":"Acute myeloid leukemia: A rare cause of acquired isolated factor VII deficiency","authors":"Zaineb Mlayah, Haifa Hafsa, Alaa Ghorbel, Nader Slama, Sara Boukhris, Mohamed-Adnene Laatiri","doi":"10.1016/j.lrr.2025.100516","DOIUrl":"10.1016/j.lrr.2025.100516","url":null,"abstract":"<div><h3>Background</h3><div>Acquired factor VII deficiency remains a rare pathology. Only 5 prior reported cases of aFVIID associated with acute myeloid leukemia (AML) have been described in the literature. Despite the rarity of these occurrences, these cases hold significant clinical and scientific implications given the need to understand the physopathology and to establish a therapeutic protocol ensuring better management.</div></div><div><h3>Case presentation</h3><div>A 38-year-old Arab male with AML was diagnosed at our Department of Clinical Hematology. The initial coagulation panel at admission revealed slightly low prothrombin ratio (PT) of 56 %, while the international normalized ratio (INR) and partial thromboplastin time (PTT) were within normal. Prothrombin complex coagulation factor dosing (PCCFD) confirmed an isolated reduction in the FVII in repeated samples, indicating an isolated deficiency. This patient did not present severe bleeding syndrome and had received conventional chemotherapy (cytarabine (Cytarabine)+ idarubicin). The evolution was marked by cytological remission (CR) with correction of coagulation disorders.</div></div><div><h3>Conclusion</h3><div>In conclusion, the intricate relationship between isolated aFVIID and AML remains mysterious. Researchers are essential to unravel the intricacies of this rare hematological condition. Further exploration into the molecular mechanisms, prognostic implications, and evolving treatment modalities is crucial to enhance the precision and efficacy of therapeutic interventions.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100516"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144124486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2025-07-10DOI: 10.1016/j.lrr.2025.100527
Zsolt Szakács , Tamás Habon , László Kereskai , László Gopcsa , Hussain Alizadeh
Background
Clinical presentation in acute myeloid leukaemia (AML) can result in a wide variety of clinical phenotypes.
Case Report
We report the case of a 34-year-old woman who presented with severe peri‑myocarditis and concomitant AML. The patient was treated with 5-azacitidine and venetoclax followed by haploidentical allogenic haematopoetic stem cell transplantation. Unfortunately, the patient developed febrile neutropenia and died because of overwhelming neutropenic sepsis. On autopsy, no evidence of AML was identified neither in bone marrow nor in cardiac tissue.
Conclusion
With this case report, we would like to emphasize the possibility of cardiac involvement in AML as well as the potential application of novel therapeutic agents in AML patients unfit for intensive chemotherapy.
{"title":"Case report: A young woman with acute peri‑myocarditis and acute myeloid leukaemia with myelodysplasia-related changes","authors":"Zsolt Szakács , Tamás Habon , László Kereskai , László Gopcsa , Hussain Alizadeh","doi":"10.1016/j.lrr.2025.100527","DOIUrl":"10.1016/j.lrr.2025.100527","url":null,"abstract":"<div><h3>Background</h3><div>Clinical presentation in acute myeloid leukaemia (AML) can result in a wide variety of clinical phenotypes.</div></div><div><h3>Case Report</h3><div>We report the case of a 34-year-old woman who presented with severe peri‑myocarditis and concomitant AML. The patient was treated with 5-azacitidine and venetoclax followed by haploidentical allogenic haematopoetic stem cell transplantation. Unfortunately, the patient developed febrile neutropenia and died because of overwhelming neutropenic sepsis. On autopsy, no evidence of AML was identified neither in bone marrow nor in cardiac tissue.</div></div><div><h3>Conclusion</h3><div>With this case report, we would like to emphasize the possibility of cardiac involvement in AML as well as the potential application of novel therapeutic agents in AML patients unfit for intensive chemotherapy.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100527"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144654380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号